New pill aims to tame nasty side effects of popular Weight-Loss drugs
NCT ID NCT06500429
Summary
This study tested whether a new oral medication called NG101 could help manage the common stomach-related side effects (like nausea) that people often experience when starting GLP-1 weight-loss drugs like semaglutide. In this completed Phase 2 trial, 120 healthy adults with a BMI between 22 and 35 received either NG101 or a placebo pill for 5 days, along with a single injection of semaglutide. Researchers compared the two groups to see if NG101 reduced the number, severity, and duration of stomach issues.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for OVERWEIGHT AND OBESITY are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Celerion
Tempe, Arizona, 85283, United States
Conditions
Explore the condition pages connected to this study.